Lymphohistiocytosis, Hemophagocytic Recruiting Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Hemophagocytic Lymphohistiocytosis / Erythrophagia / Histiocytosis hematophagic / Histiocytosis haematophagic / Haemophagocytosis / Hemophagocytosis / Haemophagocytic lymphohistiocytosis / Familial hemophagocytic reticulosis

IndicationStatusPhase
DBCOND0001493 (Lymphohistiocytosis, Hemophagocytic)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01821781Immune Disorder HSCT ProtocolTreatment